metformin has been researched along with Rheumatoid Arthritis in 14 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This was a double-blind placebo-controlled study, 120 adult patients with active rheumatoid arthritis (RA) were randomized to receive MET (1000 mg) or placebo daily with methotrexate (MTX, 7." | 9.41 | The AMPK modulator metformin as adjunct to methotrexate in patients with rheumatoid arthritis: A proof-of-concept, randomized, double-blind, placebo-controlled trial. ( Abdallah, MS; Abdelsattar Zaki, S; Abo Mansour, HE; Alarfaj, SJ; El-Naggar, ME; Elsawah, HK; Elsokary, MA; Mosalam, EM; Saif, DS; Wahsh, EA, 2021) |
| "To discussing metformin effects on rheumatoid arthritis complications." | 9.01 | Metformin one in a Million Efficient Medicines for Rheumatoid Arthritis Complications: Inflammation, Osteoblastogenesis, Cardiovascular Disease, Malignancies. ( Haybar, H; Mowla, K; Rajaei, E; Zayeri, ZD, 2019) |
| " Metformin is used for the treatment of type 2 diabetes and was reported to exert therapeutic effects against rheumatoid arthritis and obesity by improving mitochondrial dysfunction via the activation of fibroblast growth factor 21." | 7.96 | Metformin rescues rapamycin-induced mitochondrial dysfunction and attenuates rheumatoid arthritis with metabolic syndrome. ( Cho, ML; Choi, JW; Jung, KA; Kim, DS; Kim, EK; Lee, SY; Min, HK; Na, HS; Park, SH; Ryu, JG, 2020) |
| " Metformin has been reported to have a therapeutic effect on RA and obesity." | 7.88 | Metformin ameliorates experimental-obesity-associated autoimmune arthritis by inducing FGF21 expression and brown adipocyte differentiation. ( Cho, ML; Choi, JY; Jhun, JY; Kim, EK; Kim, JK; Kim, SY; Lee, SH; Lee, SY; Na, HS; Park, SH; Yang, CW, 2018) |
| "This was a double-blind placebo-controlled study, 120 adult patients with active rheumatoid arthritis (RA) were randomized to receive MET (1000 mg) or placebo daily with methotrexate (MTX, 7." | 5.41 | The AMPK modulator metformin as adjunct to methotrexate in patients with rheumatoid arthritis: A proof-of-concept, randomized, double-blind, placebo-controlled trial. ( Abdallah, MS; Abdelsattar Zaki, S; Abo Mansour, HE; Alarfaj, SJ; El-Naggar, ME; Elsawah, HK; Elsokary, MA; Mosalam, EM; Saif, DS; Wahsh, EA, 2021) |
| "To discussing metformin effects on rheumatoid arthritis complications." | 5.01 | Metformin one in a Million Efficient Medicines for Rheumatoid Arthritis Complications: Inflammation, Osteoblastogenesis, Cardiovascular Disease, Malignancies. ( Haybar, H; Mowla, K; Rajaei, E; Zayeri, ZD, 2019) |
| " Metformin is used for the treatment of type 2 diabetes and was reported to exert therapeutic effects against rheumatoid arthritis and obesity by improving mitochondrial dysfunction via the activation of fibroblast growth factor 21." | 3.96 | Metformin rescues rapamycin-induced mitochondrial dysfunction and attenuates rheumatoid arthritis with metabolic syndrome. ( Cho, ML; Choi, JW; Jung, KA; Kim, DS; Kim, EK; Lee, SY; Min, HK; Na, HS; Park, SH; Ryu, JG, 2020) |
| " Metformin has been reported to have a therapeutic effect on RA and obesity." | 3.88 | Metformin ameliorates experimental-obesity-associated autoimmune arthritis by inducing FGF21 expression and brown adipocyte differentiation. ( Cho, ML; Choi, JY; Jhun, JY; Kim, EK; Kim, JK; Kim, SY; Lee, SH; Lee, SY; Na, HS; Park, SH; Yang, CW, 2018) |
| "Metformin is a first-line therapeutic agent for type 2 diabetes." | 2.82 | Metformin and its therapeutic applications in autoimmune inflammatory rheumatic disease. ( Choe, JY; Kim, JW; Park, SH, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 5 (35.71) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, JW | 1 |
| Choe, JY | 1 |
| Park, SH | 4 |
| Lu, CH | 1 |
| Chung, CH | 1 |
| Lee, CH | 1 |
| Su, SC | 1 |
| Liu, JS | 1 |
| Lin, FH | 1 |
| Tsao, CH | 1 |
| Hsieh, PS | 1 |
| Hung, YJ | 1 |
| Hsieh, CH | 1 |
| Chien, WC | 1 |
| Naffaa, ME | 1 |
| Rosenberg, V | 1 |
| Watad, A | 1 |
| Tiosano, S | 1 |
| Yavne, Y | 1 |
| Chodick, G | 1 |
| Amital, H | 1 |
| Shalev, V | 1 |
| Kim, EK | 3 |
| Min, HK | 1 |
| Lee, SY | 3 |
| Kim, DS | 1 |
| Ryu, JG | 1 |
| Na, HS | 2 |
| Jung, KA | 1 |
| Choi, JW | 1 |
| Cho, ML | 3 |
| Zemedikun, DT | 1 |
| Gokhale, K | 1 |
| Chandan, JS | 1 |
| Cooper, J | 1 |
| Lord, JM | 1 |
| Filer, A | 1 |
| Falahee, M | 1 |
| Nirantharakumar, K | 1 |
| Raza, K | 1 |
| Abdallah, MS | 1 |
| Alarfaj, SJ | 1 |
| Saif, DS | 1 |
| El-Naggar, ME | 1 |
| Elsokary, MA | 1 |
| Elsawah, HK | 1 |
| Abdelsattar Zaki, S | 1 |
| Wahsh, EA | 1 |
| Abo Mansour, HE | 1 |
| Mosalam, EM | 1 |
| Lee, SH | 1 |
| Kim, JK | 1 |
| Jhun, JY | 1 |
| Kim, SY | 1 |
| Choi, JY | 1 |
| Yang, CW | 1 |
| Rajaei, E | 1 |
| Haybar, H | 1 |
| Mowla, K | 1 |
| Zayeri, ZD | 1 |
| Abboud, G | 1 |
| Choi, SC | 1 |
| Kanda, N | 1 |
| Zeumer-Spataro, L | 1 |
| Roopenian, DC | 1 |
| Morel, L | 1 |
| Chen, K | 1 |
| Lin, ZW | 1 |
| He, SM | 1 |
| Wang, CQ | 1 |
| Yang, JC | 1 |
| Lu, Y | 1 |
| Xie, XB | 1 |
| Li, Q | 1 |
| Kim, SC | 1 |
| Schneeweiss, S | 1 |
| Glynn, RJ | 1 |
| Doherty, M | 1 |
| Goldfine, AB | 1 |
| Solomon, DH | 1 |
| Son, HJ | 1 |
| Lee, J | 1 |
| Park, MJ | 1 |
| Kim, KW | 1 |
| Wang, H | 1 |
| Li, T | 1 |
| Chen, S | 1 |
| Gu, Y | 1 |
| Ye, S | 1 |
| Laursen, B | 1 |
| Gormsen, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients[NCT05298670] | Phase 2 | 80 participants (Anticipated) | Interventional | 2022-02-01 | Recruiting | ||
| The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial.[NCT04068246] | Phase 1/Phase 2 | 120 participants (Actual) | Interventional | 2019-08-01 | Completed | ||
| A Multicenter, Randomised, Double-blind Placebo Controlled Trial on the Efficacy and Safety of add-on Metformin to Conventional Immunosuppressants in Systemic Lupus Erythematosus[NCT02741960] | Phase 4 | 180 participants (Actual) | Interventional | 2016-05-24 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for metformin and Rheumatoid Arthritis
| Article | Year |
|---|---|
Metformin and its therapeutic applications in autoimmune inflammatory rheumatic disease.
Topics: AMP-Activated Protein Kinases; Arthritis, Rheumatoid; Diabetes Mellitus, Type 2; Humans; Metformin; | 2022 |
Metformin one in a Million Efficient Medicines for Rheumatoid Arthritis Complications: Inflammation, Osteoblastogenesis, Cardiovascular Disease, Malignancies.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Bone and Bones; Bone Diseases; Cardiovascular | 2019 |
2 trials available for metformin and Rheumatoid Arthritis
| Article | Year |
|---|---|
The AMPK modulator metformin as adjunct to methotrexate in patients with rheumatoid arthritis: A proof-of-concept, randomized, double-blind, placebo-controlled trial.
Topics: Adjuvants, Immunologic; Adult; AMP-Activated Protein Kinases; Antirheumatic Agents; Arthritis, Rheum | 2021 |
The AMPK modulator metformin as adjunct to methotrexate in patients with rheumatoid arthritis: A proof-of-concept, randomized, double-blind, placebo-controlled trial.
Topics: Adjuvants, Immunologic; Adult; AMP-Activated Protein Kinases; Antirheumatic Agents; Arthritis, Rheum | 2021 |
The AMPK modulator metformin as adjunct to methotrexate in patients with rheumatoid arthritis: A proof-of-concept, randomized, double-blind, placebo-controlled trial.
Topics: Adjuvants, Immunologic; Adult; AMP-Activated Protein Kinases; Antirheumatic Agents; Arthritis, Rheum | 2021 |
The AMPK modulator metformin as adjunct to methotrexate in patients with rheumatoid arthritis: A proof-of-concept, randomized, double-blind, placebo-controlled trial.
Topics: Adjuvants, Immunologic; Adult; AMP-Activated Protein Kinases; Antirheumatic Agents; Arthritis, Rheum | 2021 |
Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-of-Concept Trial of Metformin.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Arthritis, Rheumatoid; Autoantibodies; Case-Control Stud | 2015 |
10 other studies available for metformin and Rheumatoid Arthritis
| Article | Year |
|---|---|
Combination of COX-2 inhibitor and metformin attenuates rate of admission in patients with rheumatoid arthritis and diabetes in Taiwan.
Topics: Aged; Arthritis, Rheumatoid; Cyclooxygenase 2 Inhibitors; Databases, Factual; Diabetes Mellitus, Typ | 2019 |
Adherence to metformin and the onset of rheumatoid arthritis: a population-based cohort study.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Diabetes Mellitus, Type 2; | 2020 |
Metformin rescues rapamycin-induced mitochondrial dysfunction and attenuates rheumatoid arthritis with metabolic syndrome.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Drug Therapy, Combination; Hypoglycemic Age | 2020 |
Type 2 diabetes mellitus, glycaemic control, associated therapies and risk of rheumatoid arthritis: a retrospective cohort study.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Glucose; Databases, Fact | 2021 |
Metformin ameliorates experimental-obesity-associated autoimmune arthritis by inducing FGF21 expression and brown adipocyte differentiation.
Topics: Adipocytes, Brown; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Arthri | 2018 |
Inhibition of Glycolysis Reduces Disease Severity in an Autoimmune Model of Rheumatoid Arthritis.
Topics: Animals; Arthritis, Rheumatoid; Autoantibodies; CD4-Positive T-Lymphocytes; Deoxyglucose; Disease Mo | 2018 |
Metformin inhibits the proliferation of rheumatoid arthritis fibroblast-like synoviocytes through IGF-IR/PI3K/AKT/m-TOR pathway.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Arthritis, Rheumatoid; Cell Cycle; Cell Cycle Prote | 2019 |
Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study.
Topics: Arthritis, Rheumatoid; Autoimmune Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Pe | 2015 |
Metformin attenuates experimental autoimmune arthritis through reciprocal regulation of Th17/Treg balance and osteoclastogenesis.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Cell Differentiation; Interleukin-17; Male; | 2014 |
Pharmacological enhancement and short-term stimulation of blood fibrinolytic activity.
Topics: Adolescent; Adult; Aged; Aminocaproates; Anticholesteremic Agents; Arteriosclerosis; Arthritis, Rheu | 1969 |